417 related articles for article (PubMed ID: 32358833)
1. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.
Alexander SPH; Armstrong JF; Davenport AP; Davies JA; Faccenda E; Harding SD; Levi-Schaffer F; Maguire JJ; Pawson AJ; Southan C; Spedding M
Br J Pharmacol; 2020 Nov; 177(21):4942-4966. PubMed ID: 32358833
[TBL] [Abstract][Full Text] [Related]
2. Current pharmacological treatments for COVID-19: What's next?
Scavone C; Brusco S; Bertini M; Sportiello L; Rafaniello C; Zoccoli A; Berrino L; Racagni G; Rossi F; Capuano A
Br J Pharmacol; 2020 Nov; 177(21):4813-4824. PubMed ID: 32329520
[TBL] [Abstract][Full Text] [Related]
3. Targeting zinc metalloenzymes in coronavirus disease 2019.
Doboszewska U; Wlaź P; Nowak G; Młyniec K
Br J Pharmacol; 2020 Nov; 177(21):4887-4898. PubMed ID: 32671829
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H
Citi V; Martelli A; Brancaleone V; Brogi S; Gojon G; Montanaro R; Morales G; Testai L; Calderone V
Br J Pharmacol; 2020 Nov; 177(21):4931-4941. PubMed ID: 32783196
[TBL] [Abstract][Full Text] [Related]
5. Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology.
Cleary SJ; Pitchford SC; Amison RT; Carrington R; Robaina Cabrera CL; Magnen M; Looney MR; Gray E; Page CP
Br J Pharmacol; 2020 Nov; 177(21):4851-4865. PubMed ID: 32462701
[TBL] [Abstract][Full Text] [Related]
6. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19.
Robb CT; Goepp M; Rossi AG; Yao C
Br J Pharmacol; 2020 Nov; 177(21):4899-4920. PubMed ID: 32700336
[TBL] [Abstract][Full Text] [Related]
7. Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19?
Sriram K; Insel PA
Br J Pharmacol; 2020 Nov; 177(21):4971-4974. PubMed ID: 32639031
[TBL] [Abstract][Full Text] [Related]
8. Statins: Could an old friend help in the fight against COVID-19?
Rodrigues-Diez RR; Tejera-Muñoz A; Marquez-Exposito L; Rayego-Mateos S; Santos Sanchez L; Marchant V; Tejedor Santamaria L; Ramos AM; Ortiz A; Egido J; Ruiz-Ortega M
Br J Pharmacol; 2020 Nov; 177(21):4873-4886. PubMed ID: 32562276
[TBL] [Abstract][Full Text] [Related]
9. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.
Bertocchi I; Foglietta F; Collotta D; Eva C; Brancaleone V; Thiemermann C; Collino M
Br J Pharmacol; 2020 Nov; 177(21):4921-4930. PubMed ID: 32776354
[TBL] [Abstract][Full Text] [Related]
10. The potential of cannabidiol in the COVID-19 pandemic.
Esposito G; Pesce M; Seguella L; Sanseverino W; Lu J; Corpetti C; Sarnelli G
Br J Pharmacol; 2020 Nov; 177(21):4967-4970. PubMed ID: 32519753
[TBL] [Abstract][Full Text] [Related]
11. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
Tamimi F; Abusamak M; Akkanti B; Chen Z; Yoo SH; Karmouty-Quintana H
Br J Pharmacol; 2020 Nov; 177(21):4845-4850. PubMed ID: 32442317
[TBL] [Abstract][Full Text] [Related]
12. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance.
Sriram K; Insel PA
Br J Pharmacol; 2020 Nov; 177(21):4825-4844. PubMed ID: 32333398
[TBL] [Abstract][Full Text] [Related]
13. A rationale for targeting the P2X7 receptor in Coronavirus disease 19.
Di Virgilio F; Tang Y; Sarti AC; Rossato M
Br J Pharmacol; 2020 Nov; 177(21):4990-4994. PubMed ID: 32441783
[TBL] [Abstract][Full Text] [Related]
14. A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019.
Colarusso C; Terlizzi M; Pinto A; Sorrentino R
Br J Pharmacol; 2020 Nov; 177(21):4866-4872. PubMed ID: 32497257
[TBL] [Abstract][Full Text] [Related]
15. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
16. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.
Wang Y; Chen L
Br J Pharmacol; 2020 Nov; 177(21):4995-4996. PubMed ID: 32424836
[No Abstract] [Full Text] [Related]
17. Databases for the targeted COVID-19 therapeutics.
Wang Y; Li F; Zhang Y; Zhou Y; Tan Y; Chen Y; Zhu F
Br J Pharmacol; 2020 Nov; 177(21):4999-5001. PubMed ID: 32845521
[No Abstract] [Full Text] [Related]
18. Discovering small-molecule therapeutics against SARS-CoV-2.
Tiwari V; Beer JC; Sankaranarayanan NV; Swanson-Mungerson M; Desai UR
Drug Discov Today; 2020 Aug; 25(8):1535-1544. PubMed ID: 32574699
[TBL] [Abstract][Full Text] [Related]
19. Combating devastating COVID-19 by drug repurposing.
Pawar AY
Int J Antimicrob Agents; 2020 Aug; 56(2):105984. PubMed ID: 32305589
[TBL] [Abstract][Full Text] [Related]
20. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
Pandey A; Nikam AN; Shreya AB; Mutalik SP; Gopalan D; Kulkarni S; Padya BS; Fernandes G; Mutalik S; Prassl R
Life Sci; 2020 Sep; 256():117883. PubMed ID: 32497632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
